$BOLD

Boundless Bio, Inc.

Boundless Bio is a clinical-stage oncology company developing small-molecule therapies for patients with oncogene-amplified cancers. Its proprietary Spyglass platform examines extrachromosomal DNA (ecDNA) biology to identify cancer-cell vulnerabilities, which the company uses to discover ecDNA-directed therapeutic candidates designed to disrupt the cellular machinery that enables ecDNA to function. Its lead candidate, BBI-940, is an oral selective degrader being studied in the Phase 1 KOMODO-1 trial in patients with certain types of breast cancer. Boundless Bio has also developed BBI-355 and BBI-825; it elected to cease enrollment in the BBI-355 POTENTIATE trial in January 2026. Boundless Bio develops its own drug candidates and retains global rights to its programs. It is headquartered in La Jolla, California.

No enriched coverage for $BOLD in the last 7 days.

$215K
—
TANG KEVIN
0%
See all $BOLD insider activity →
Low

TANG KEVIN purchased $33K of BOLD (indirect holdings)

TANG KEVIN purchased 13,812 indirectly-held shares of Boundless Bio, Inc. (BOLD) at $2.40 across 2 trades over 2026-11-13 to 2026-11-17. Filed jointly with TANG CAPITAL MANAGEMENT LLC (10% owner).

Boundless Bio 3Q 2026: EPS ($0.23) — 10-Q Summary

Boundless Bio reported a 61.4% narrower net loss of $5.36M in Q3 2026, with EPS at ($0.23). The reduction was driven by lower clinical-trial spending, reduced facilities, and personnel costs. The company also announced a 75% workforce reduction and expects a merger with Serapha Bio to close in Q4 2026, with a pre-closing dividend of $44M-$48M.

TANG KEVIN purchased $27K of BOLD (indirect holdings)

TANG KEVIN purchased 11,162 indirectly-held shares of Boundless Bio, Inc. (BOLD) at $2.40 across 3 trades over 2026-11-03 to 2026-11-05. Filed jointly with TANG CAPITAL MANAGEMENT LLC (10% owner).

BOLD sentiment & insider activity

Recent BOLD coverage spans insider activity, market movers and earnings.

In the last 30 days, BOLD insiders filed 14 SEC Form 4 transactions — 14 purchases ($215K) and no sales. The most active reporter was TANG KEVIN with 14 filings.

What's driving BOLD

AlphAI scores every news story that mentions BOLD with an AI model for sentiment and relevance, and aggregates insider trades from Boundless Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $BOLD

Score

Boundless Bio 3Q 2026: EPS ($0.23) — 10-Q Summary

Boundless Bio reported a 61.4% narrower net loss of $5.36M in Q3 2026, with EPS at ($0.23). The reduction was driven by lower clinical-trial spending, reduced facilities, and personnel costs. The company also announced a 75% workforce reduction and expects a merger with Serapha Bio to close in Q4 2026, with a pre-closing dividend of $44M-$48M.

Top insider buys and sells disclosed on Tuesday

Insider trading activity for US-listed stocks on Tuesday included significant purchases and sales. Saba Capital bought 338,104 shares of BNY Mellon Strategic Municipals (LEO) at $5.63-$5.67. Nippon Life bought 347,195 shares of Corebridge Financial (CRBG) at $34.31-$35.07. Kevin Tang increased his stake in Boundless Bio (BOLD) with purchases totaling $349,592. Smriti Popenoe bought $156,560 of Dynex Capital (DX) stock. David Sims acquired $108,632 of Eagle Capital Growth Fund (GRF) shares.

$BOLDMedM&A· acquirer · definitive

Boundless Bio, Inc. (BOLD): Entry into a Material Definitive Agreement

Boundless Bio, Inc. (BOLD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously announced, on June 22, 2026, Boundless Bio, Inc., a Delaware corporation (“Boundless Bio”), Boulder Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of Boundless Bio (“Merger Sub”), and Seraph

Biotech Stocks At 52-Week Highs - ELOX, PRLD, ARGX, BOLD, CORT

Several biotech stocks hit 52-week highs on August 21, 2026. Eloxx (ELOX) rose 16% to $23.40, reporting a Q2 net loss of $4.5M. argenX (ARGX) reached $1,058.69, with positive trial results for VYVGART. Corcept (CORT) hit $123.44, reporting $256M in Q2 revenue. Boundless Bio (BOLD) reached $3.02, initiating a first-in-human trial. Prelude (PRLD) peaked at $6.38, advancing JAK2V617F in Phase 1 trials.

Related tickers